Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9704969 | 0.98 | MAPT (0.62) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| Iodide SCHEMBL30309834 | 0.98 | MAPT (0.62) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL27605420 | 0.98 | MAPT (0.62) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12633299 | 0.93 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12471919 | 0.93 | MAPT (0.57) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12772860 | 0.90 | CHRM1 (0.56) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL6995632 | 0.89 | MAPT (0.56) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12898087 | 0.89 | MAPT (0.56) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12898753 | 0.89 | MAPT (0.56) | MAPTALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL17284582 | 0.88 | MAPT (0.55) | MAPTALDH1A1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978765-B1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA SAU (ES) | 2018-05-02 | — | — | EP | claimed |
| US-9682984-B2 | Methods for the preparation of alcaftadine | CRYSTAL PHARMA S.A.U. (ES) | 2017-06-20 | — | — | US | claimed |
| US-20160280709-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA S.A.U. (ES) | 2016-09-29 | — | — | US | claimed |
| EP-2978765-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | Crystal Pharma S.A.U (ES) | 2016-02-03 | — | — | EP | claimed |
| WO-2014154620-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA S.A.U. (ES) | 2014-10-02 | — | — | WO | claimed |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| CN-113045540-B | Preparation method of masmipide | 上海天慈国际药业有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117105909-A | Preparation method of intermediate of lasmidbody | 山东新时代药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230203035-A1 | Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-113321640-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-09 | — | — | CN | disclosed |
| CN-109111427-B | Indole compound and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-06-02 | — | — | CN | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| US-5106851-A | Respiratory system disorders | ISTITUTO DE ANGELI S.P.A. (IT) | 1992-04-21 | — | — | US | disclosed |
| US-5102890-A | Anxiolytic agents | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
| US-5030641-A | Treatment of angina pectoris, hypotensive agents | BOEHRINGER MANNHEIM GMBH (DE) | 1991-07-09 | — | — | US | disclosed |
| EP-0382687-A2 | Benzofused-N-containing heterocycle derivatives | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
| EP-0326526-A1 | Aminoketones of substituted dibenzo- and pyridobenzo-azepinones and pharmaceutical compositions | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
| US-4757079-A | Hypotensive agents | DYNAMAC CORPORATON (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0239309-A2 | Oxadiazoles useful in the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | MAPT 1499/4885ALDH1A1 2547/4885KDM4E 547/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | MAPT 3504/4885ALDH1A1 3005/4885KDM4E 212/4885 |
| US-20230203035-A1 | Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | MAPT 3433/4885ALDH1A1 1483/4885KDM4E 2286/4885 |
| US-20160280709-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | NISCH, CMA1, ADRA2C | MAPT 2221/4885ALDH1A1 173/4885KDM4E 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.